VolitionRx Limited (VNRX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. VolitionRx Limited is a multi-national epigenetics company developing blood tests for early detection of cancer and sepsis. The company operates in a pre-profitability stage, focusing on commercializing its Nu.Q® product suite (veterinary and human diagnostics) and securing licensing agreements. As of May 7, 2026, there were 8,330,270 shares of common stock issued and outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $985,076 | $246,385 |
| Net Loss | $(6,703,557) | $(5,476,627) |
| Operating Loss | $(5,348,852) | $(5,521,720) |
| Cash and Cash Equivalents (End of Period) | $3,102,817 | $2,600,342 |
| Net Cash Used in Operating Activities | $(5,280,132) | $(4,298,018) |
| Net Cash Provided by Financing Activities | $7,616,176 | $3,667,080 |
| Total Current Liabilities | $13,567,421 | $12,230,753 |
| Stockholders' Deficit | $(33,359,929) | $(35,592,811) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by approximately 300% to $0.99 million, driven primarily by a $0.79 million increase in product revenue. This was largely due to a catch-up recognition of deferred revenue related to the Heska veterinary agreement.
- Expense Increases: Operating expenses rose 10% to $6.33 million. Research and Development (R&D) expenses increased by $0.24 million due to direct costs for lung cancer studies in Taiwan and France. General and Administrative (G&A) expenses increased by $0.39 million, primarily due to higher legal and professional fees related to financing activities.
- Net Loss Expansion: Net loss increased by $1.23 million (22%) to $6.70 million. This was significantly impacted by non-cash charges, including a $1.01 million loss on extinguishment of debt and $0.45 million in amortization of debt discount related to convertible notes.
- Liquidity Improvement: Cash balances increased by $1.99 million during the quarter, funded by $5.17 million in proceeds from common stock issuances (ATM program) and $1.76 million from convertible note issuances.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year from the date of issuance. The company relies on raising additional capital through equity, debt, or licensing to sustain operations.
- Commercialization: The company is actively pursuing reimbursement for its Nu.Q® NETs test in Europe and the Nu.Q® Lung Cancer test in France. It has signed agreements with major partners including Werfen, Hologic, Antech, and IDEXX.
- Debt Obligations: The company holds significant convertible notes (2025 and 2026 Lind Notes) with complex repayment terms involving cash or stock issuance. Failure to meet these obligations could trigger default penalties.
- Internal Controls: The company identified a material weakness in internal control over financial reporting due to insufficient written documentation of policies and procedures. Remediation plans are underway.
- Reverse Stock Split: A 1-for-20 reverse stock split was effected on April 28, 2026. All share data in this report has been retroactively adjusted.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.1 million cash balance against the $13.6 million in current liabilities and ongoing burn rate of ~$5.3 million per quarter.
- Debt Repayment Terms: Review the specific terms of the Lind convertible notes, particularly the "Repayment Share Price" mechanism and the risk of dilution or default penalties (120% of principal).
- Revenue Sustainability: Assess whether the Q1 revenue spike was a one-time accounting adjustment (deferred revenue catch-up) or indicative of recurring commercial sales.
- Internal Control Remediation: Monitor progress on fixing the material weakness in financial reporting controls to ensure future financial statement reliability.
- Regulatory Milestones: Track the status of reimbursement applications for the Nu.Q® NETs and Lung Cancer tests, which are critical for future revenue scaling.